Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients
Dermatology
Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.
Type 2 Inflammation Contributes to Itch and Fibrois in PN
Dermatology
Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.
The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
Dr. Lisa Beck highlights the association between epidermal barrier dysfunction and S. aureus colonization in her talk at the ISDS 2023 ADVENT symposium.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
